Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism

Breast Cancer Research

Volumn 10, Issue 3, 2008, Pages

  Androutsopoulos, Vasilis ^a   Arroo, Randolph R J ^a   Hall, John F ^a   Surichan, Somchaiya ^a   Potter, Gerry A ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; EUPATORIN; FLAVONOID; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BREAST; CELL PROLIFERATION; DRUG EFFECT; HUMAN; IC 50; METABOLISM; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; FLAVONOIDS; HUMANS; INHIBITORY CONCENTRATION 50; TETRAZOLIUM SALTS; THIAZOLES;

EID: 55749110433     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2090     Document Type: Article

References (32)

1. Draper L. Breast cancer: trends, risks, treatments and effects. AAOHN J 2006, 54:445-451.
2. Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother 2007, 8:119-127. 10.1517/14656566.8.2.119, 17257083.
3. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary and workshop proceedings. J Natl Cancer Inst 2006, 98:1275-1284.
4. Verheus M, van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters PH. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007, 25:648-655. 10.1200/JCO.2006.06.0244, 17200150.
5. Tezuka Y, Stampoulis P, Banskota AH, Awale S, Tran KQ, Saiki I, Kadota S. Constituents of the Vietnamese medicinal plant Orthosiphon stamineus. Chem Pharm Bull 2000, 48:1711-1719.
6. Nagao T, Abe F, Kinjo J, Okabe H. Antiproliferative constituents in plants 10. Flavones from the leaves of Lantana montevidensis Briq. and consideration of structure-activity relationship. Biol Pharm Bull 2002, 25:875-879. 10.1248/bpb.25.875, 12132661.
7. Schinella GR, Giner RM, Recio MC, Mordujovich de Buschiazzo P, Rios JL, Manez S. Anti-inflammatory effects of south American Tanacetum vulgare. J Pharm Pharmacol 1998, 50:1069-1074.
8. McFadyen MCE, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004, 3:363-371.
9. Rooney PH, Telfer C, McFadyen MC, Melvin WT, Murray GI. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets 2004, 4:257-265. 10.2174/1568009043333014, 15134533.
10. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res 2005, 65:3726-3734. 10.1158/0008-5472.CAN-04-3771, 15867368.
11. Murray GI, Shaw D, Weaver RJ, McKay JA, Ewen SW, Melvin WT, Burke MD. Cytochrome P450 expression in oesophageal cancer. Gut 1994, 35:599-603. 1374739, 8200549, 10.1136/gut.35.5.599.
12. Nakajima T, Wang RS, Nimura Y, Pin YM, He M, Vainio H, Murayama N, Aoyama T, Iida F. Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous cell carcinomas. Carcinogenesis 1996, 17:1477-1481. 10.1093/carcin/17.7.1477, 8706252.
13. Murray GI, Taylor MC, McFadyen MCE, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor specific expression of cytochrome P450 CYP1B1. Cancer Res 1997, 57:3026-3031.
14. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA, Burke MD. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 2002, 86:774-778. 10.1038/sj.bjc.6600197, 11875742.
15. Brantley E, Trapani V, Alley MC, Hose CD, Bradshaw TD, Stevens MF, Sausville EA, Stinson SF. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolised, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos 2004, 32:1392-1401. 10.1124/dmd.104.001057, 15355884.
16. Patterson LH, Murray GI. Tumor cytochrome P450 and drug activation. Curr Pharm Des. 2002, 8:1335-1347. 12052211, 10.2174/1381612023394502.
17. Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos 1997, 25:1298-1303.
18. Atherton K, Mutch E, Ford D. Metabolism of the soyabean isoflavone daidzein by CYP1A2 and the extra-hepatic CYPs 1A1 and 1B1 affects biological activity. Biochem Pharmacol 2006, 72:624-631. 10.1016/j.bcp.2006.05.015, 16814747.
19. Wen X, Walle T. Preferential induction of CYP1B1 by benzo[a]pyrene in human oral epithelial cells: impact on DNA adduct formation and prevention by polyphenols. Carcinogenesis 2005, 26:1774-1781. 10.1093/carcin/bgi127, 15905203.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principles of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
21. Doostdar H, Burke MD, Mayer RT. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000, 144:31-38. 10.1016/S0300-483X(99)00215-2, 10781868.
22. Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MF. Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 2000, 60:5196-5203.
23. Wang WL, Porter W, Burghardt R, Safe SH. Mechanism of inhibition of MDA-MB 468 breast cancer cell growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Carcinogenesis 1997, 18:925-933. 10.1093/carcin/18.5.925, 9163677.
24. Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, Li Y, Sutter TR. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998, 19:291-298. 10.1093/carcin/19.2.291, 9498279.
25. Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, Guengerich FP. Selectivity of polycyclic inhibitors for human cytochromes P450 1A1, 1A2 and 1B1. Chem Res Toxicol 1998, 11:1048-1056. 10.1021/tx980090+, 9760279.
26. Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 2004, 3:715-725.
27. Vasselin DA, Westwell AD, Matthews CS, Bradshaw TD, Stevens MF. Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzothiazoles. J Med Chem 2006, 49:3973-3981. 10.1021/jm060359j, 16789754.
28. Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brøsen K, Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 2002, 40:609-616. 10.1016/S0278-6915(01)00125-9, 11955666.
29. Otake Y, Walle T. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2 and CYP2C9. Drug Metab Dispos 2002, 30:103-105. 10.1124/dmd.30.2.103, 11792676.
30. Shi Q, Chen K, Li L, Chang JJ, Autry C, Kozuka M, Konoshima T, Estes JR, Lin CM, Hamel E. Antitumor agents 154. Cytotoxic and antimitotic flavonols from Polanisia dodecandra. J Nat Prod 1995, 58:475-482. 10.1021/np50118a001, 7623025.
31. Kobayakawa J, Sato-Nishimori F, Moriyasu M, Matsukawa Y. G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Viticis Fructus (Vitex rotundifolia Linne fil.). Cancer Lett 2004, 208:59-64. 10.1016/j.canlet.2004.01.012, 15105046.
32. Lawrence NJ, Patterson RP, Ooi LL, Cook D, Ducki S. Effects of α-substitutions on structure and biological activity of anticancer chalcones. Bioorg Med Chem Lett 2006, 16:5844-5848. 10.1016/j.bmcl.2006.08.065, 16949281.